GTCR to take Surmodics Private for $627 Million in Cash

Private equity firm GTCR has entered into a merger agreement to acquire medical device coatings maker Surmodics, Inc. (SRDX) in a $627 million all-cash deal.

Deal Structure:

As per the terms outlined in the agreement, affiliates of GTCR will acquire all the outstanding shares of Surmodics for $43.00 per share in cash, representing a premium of 22.51% from the stock’s last close.

Please subscribe for free or login to your InsideArbitrage account to access this article.